{"id":1015695,"date":"2026-10-30T07:56:10","date_gmt":"2026-10-30T11:56:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/"},"modified":"2026-10-30T07:56:10","modified_gmt":"2026-10-30T11:56:10","slug":"alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/","title":{"rendered":"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Highlights<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA)<\/li>\n<li style=\"margin-bottom:5pt\">New U.S. composition of matter patent granted for ATH434, extending protection to 2045 and supporting future development in Parkinson\u2019s disease<\/li>\n<li style=\"margin-bottom:5pt\">Peer-reviewed publication in <em>Clinical Autonomic Research<\/em> from the bioMUSE Natural History Study linked skin \u03b1-synuclein deposition to autonomic dysfunction in early MSA<\/li>\n<li style=\"margin-bottom:5pt\">Phase 3 operational activities underway<\/li>\n<li style=\"margin-bottom:5pt\">Continued evaluation of strategic funding and partnering alternatives to support Phase\u00a03 development and maximize long-term shareholder value<\/li>\n<li style=\"margin-bottom:5pt\">Cash balance of A$41.3 million at 30 September 2026, inclusive of A$3.98 million Australian R&amp;D Tax Incentive refund and approximately net A$5.5 million raised through the exercise of ATHO listed options<\/li>\n<\/ul>\n<p align=\"justify\">MELBOURNE, Australia and SAN FRANCISCO, Oct.  30, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jn5RjVhCqs0TspLRb4fKieXyn-7RMRklZaBDu47ZSlJY3zKQbBna3V_y4C1N8Ja_Zhr5jQJHekr76xhqjYy1qaLn2DvG523aKqVaOxyz2eg=\" rel=\"nofollow\" target=\"_blank\">Alterity Therapeutics<\/a> (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2026 (Q1 FY27).<\/p>\n<p align=\"justify\">\u201cThis was a quarter of meaningful progress for Alterity,\u201d said David Stamler, M.D., Chief Executive Officer. \u201cWith the final minutes from our End-of-Phase 2 meeting, we have confirmed alignment with the FDA on the registrational pathway for ATH434 in MSA. That clarity has allowed us to begin the operational start-up activities as we prepare to initiate our Phase 3 trial in MSA.\u201d<\/p>\n<p align=\"justify\">\u201cWe also strengthened the foundation for ATH434&#8217;s long-term value. The granting of a new U.S. composition of matter patent for ATH434 extends protection to 2045 and supports its future development in Parkinson\u2019s disease. We continue to build on our scientific work with a peer-reviewed publication from the bioMUSE Natural History Study and new Phase 2 analyses presented at the MDS Congress that adds to the evidence supporting ATH434&#8217;s clinical profile and iron-chaperone mechanism. Together with the proceeds from the exercise of our listed options and receipt of our R&amp;D tax refund, our position is strengthened as we advance toward Phase 3,\u201d concluded Dr. Stamler.<\/p>\n<p>\n        <strong>Secured New ATH434 Intellectual Property Protection<\/strong>\n      <\/p>\n<p align=\"justify\">In August 2026, the United States Patent and Trademark Office (USPTO) granted a new composition of matter patent for ATH434. The patent covers a crystalline form of the mesylate salt of ATH434, the form used in the Company\u2019s Phase 2 clinical trials in MSA and planned for use in Phase 3, as well as methods for treating neurological conditions using it. The patent has an expiry of 2045 and is expected to be listed in the FDA\u2019s Orange Book upon regulatory approval of ATH434. Together with existing intellectual property and regulatory designations, including Orphan Drug Designation in the U.S. and EU, the patent provides multi-layered protection for ATH434 in MSA and supports the commercial rationale for future development in Parkinson\u2019s disease and other neurodegenerative diseases where iron dysregulation is implicated.<\/p>\n<p align=\"justify\">\n        <strong>Continued ATH434 Clinical and Regulatory Progress<\/strong>\n      <\/p>\n<p align=\"justify\">During the quarter, the Company received minutes from the U.S. Food and Drug Administration (FDA) End-of-Phase 2 (EOP2) meeting regarding the Phase 3 study design and the registrational pathway for a potential New Drug Application (NDA) for ATH434 in MSA. The minutes confirmed that the FDA agreed with the proposed Phase 3 design, including the study population, treatment regimen, and primary endpoint \u2012 the 11-item UMSARS Part I<sup>1<\/sup> rating scale, a functional measure of activities of daily living affected in MSA. Agreement was also reached on selection of key secondary endpoints. The FDA indicated that a single pivotal trial plus confirmatory evidence could provide the data necessary to support approval, with the Company anticipating that the data from its ATH434-201 Phase 2 clinical trial will provide the required confirmatory evidence.<\/p>\n<p align=\"justify\">The Phase 3 study is expected to enroll approximately 200 patients who will be randomized 1:1 to ATH434 50 mg or matching placebo treatment twice daily for 12 months. Alterity has begun Phase 3 operational activities including finalizing the protocol, selecting vendors, identifying and qualifying clinical trial sites, and successfully manufacturing the first registration batch of ATH434 for use in the pivotal trial.<\/p>\n<p>\n        <strong>Scientific Engagement<\/strong>\n      <\/p>\n<p align=\"justify\">Alterity continues to actively engage with the global neurology community through peer-reviewed publications and scientific presentations at leading international congresses. These activities form an important component of the Company\u2019s strategy to disseminate clinical data, engage with key opinion leaders and specialists, and further interpret Phase 2 results for ATH434 in MSA.<\/p>\n<p align=\"justify\">During the quarter and subsequent to quarter end, Alterity presented the following new analyses and peer-reviewed publication, which are available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hXIaq0yJr_ZRhPYV_cnQDE7eIkmXTKLSdcvVJfv6u75ttBQSGe1SR9iE7j5d1_nIj0yIYOYRw4ht45MijtoZ_r1m6Kp9oB_HrzfWLuSKXHKGu2YypaDBmeoPwS4cZarj1-yIM4gV7jq43uoya9AEoA==\" rel=\"nofollow\" target=\"_blank\">Publications and Presentations<\/a> page of the Company\u2019s website:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0.3pt;margin-bottom:12pt;text-align:justify\">October 2026 \u2013 International Congress of Parkinson\u2019s Disease and Movement Disorders (MDS Congress): Poster presented additional analyses from the ATH434-201 Phase 2 trial in MSA. Using statistical methods planned for Phase 3, the analysis showed that ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS<sup>1<\/sup> at Week 52. Baseline CSF NfL predicted the rate of functional decline, supporting its use as a severity covariate in Phase 3.<\/li>\n<li style=\"margin-top:0.3pt;text-align:justify\">August 2026 \u2013 Peer-reviewed publication in <em>Clinical Autonomic Research<\/em> from the Company\u2019s bioMUSE Natural History Study described phosphorylated \u03b1-synuclein deposition in the skin biopsies of study participants. At baseline, \u03b1-synuclein strongly correlated with the drop in blood pressure on standing (orthostatic hypotension), and after 12 months \u03b1-synuclein deposition was correlated with higher autonomic symptom scores. The findings support skin biopsy as a minimally invasive tool to support the diagnosis and monitoring of progression in MSA clinical trials.<\/li>\n<\/ul>\n<p>\n        <strong>Investor and Strategic Partner Engagement <\/strong>\n      <\/p>\n<p align=\"justify\">Alterity continues to engage with the investment communities in Australia and the U.S. with presentations at several conferences in the United States: Canaccord Genuity Growth, Cantor Global Healthcare, BTIG Biotech, and Craig-Hallum Biotech. Presentations in Australia included BioShares, ASX SMIDcaps, and the Canaccord Genuity Drug and Device Conference.<\/p>\n<p align=\"justify\">Alterity continues to evaluate a range of strategic and funding alternatives to support the advancement of ATH434, including ongoing discussions with a number of pharmaceutical companies. The Company is progressing a structured evaluation process, with the assistance of external advisers, to assess these opportunities alongside other potential funding and development pathways.<\/p>\n<p align=\"justify\">The Company remains focused on maintaining strategic flexibility while pursuing the pathway that best supports the advancement of ATH434 and maximizes long-term shareholder value.<\/p>\n<p align=\"justify\">\n        <strong>Corporate and Financial Update<\/strong>\n      <\/p>\n<p align=\"justify\">In July 2026, the Company received its research and development (R&amp;D) tax refund for the 2025 financial year totaling A$3,982,992 (including A$43,117 of interest), under the Australian Government\u2019s R&amp;D Tax Incentive.<\/p>\n<p align=\"justify\">In August 2026, the Company entered into an underwriting agreement with MST Financial Services Pty Ltd to underwrite the exercise of up to 8,400,000 of the 15,918,235 ATHO listed options on issue at the agreement date (exercisable at A$0.50 and expiring on 31 August 2026). In the quarter ending 30 September 2026, 3,191,983 options were exercised by option holders prior to expiry and 8,400,000 shortfall shares were issued under the underwriting, raising total proceeds of approximately A$5.5 million after costs. Proceeds will support continued late-stage clinical development of ATH434 in MSA and general working capital.<\/p>\n<p align=\"justify\">As of 30 September 2026, Alterity held cash and cash equivalents of A$41.3 million. Operating cash outflows for the quarter were A$1.34 million.<\/p>\n<p align=\"justify\">In accordance with ASX Listing Rule 4.7C, payments of A$323k made to related parties and their associates during the quarter included non-executive directors\u2019 fees, managing director salary, consulting fees, remuneration and superannuation at commercial rates.<\/p>\n<p align=\"justify\">The full financial report can be found in the ASX filing <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m9MQqVvjQYlN_M1SJr2-hAD-OQlfPWoC_no-R8TLyurLnjM7tHU6wDtPNfqOoBFnnG1Aw4LXSb3VCJinbmjKyozz8mlb-LgL0l8KVVVVZWA=\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Alterity Therapeutics Limited <\/strong>\n      <\/p>\n<p align=\"justify\">Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson\u2019s disease and related disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment. ATH434, the Company\u2019s lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yjjwzllIU-FN-pri2T7pF6FdDcdTXONqLr8TwG2T8gBWqdCztiqobcC_j4ZzAVbYtwKFxFG4DS-H-g4BsfyEalk9Y98xB1Wa7HI1jqaV1dA=\" rel=\"nofollow\" target=\"_blank\">https:\/\/alteritytx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>References<\/strong><br \/>\n        <br \/>\n        <sup>1 <\/sup>11-item UMSARS Part I (previously described as modified UMSARS I): Unified Multiple System Atrophy Rating Scale, 11-Items include: Orthostatic symptoms, Swallowing, Speech, Handwriting, Cutting food, Dressing, Hygiene, Walking, Falling, Urinary and Bowel function.<\/p>\n<p>\n        <strong>Authorization &amp; Additional Information<\/strong><br \/>\n        <br \/>This announcement was authorized by the Board of Directors of Alterity Therapeutics Limited.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Elyse Shapiro<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kkDUvwTuzce7zG7PY0_nzB6Rn5CI975T7clyRXLX5VmjhtDCpqwuR8PUYiQKnc9-7NtvZ3mB_mEO96SUa04ueRdlfYnLEDQQeRzB17lem0o=\" rel=\"nofollow\" target=\"_blank\">ir@alteritytx.com<\/a><\/p>\n<p>Remy Bernarda<br \/>Investor Relations Advisory Solutions<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kkDUvwTuzce7zG7PY0_nzM2hZPGtGwS4Fz3BhGdEaU9BiKpH1geRTcqUr1RWg2EQbJHMSz25mQVJEjTaA_L6z4H90Qjetet6Jk_SxaVWCcM=\" rel=\"nofollow\" target=\"_blank\">ir@alteritytx.com<\/a><br \/>+1 (415) 203-6386<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Melissa Tempra<br \/>NWR Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cv9ZqlgbABA2xDFkBqq-pD4yJKJ5eR5x8XY75EXdUnim04Rv26KVVgfYzmwq2fr_QAC256tfeTRiCDPJeOZx_hZ0OnTR0ZSHVEZbUFRJNtRNKoQ9sslsa2pEm0do8SQ2RbMRdUn7QrU1u0XTtVniRg==\" rel=\"nofollow\" target=\"_blank\">melissa@nwrcommunications.com.au<\/a><\/p>\n<p>Casey McDonald<br \/>Tiberend Strategic Advisors, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jGbLEO4Z0j9057cK-qN8wNsuH57lhGAZu9FuhMBMDhvSvKl8ob2u5OS2lc4bodT4OAyRns5rigFy5J4fER62nH1Nd0BY5uZIXcJP1Eg5lmM=\" rel=\"nofollow\" target=\"_blank\">cmcdonald@tiberend.com<\/a><br \/>+1 (646) 577-8520<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release contains &#8220;forward-looking statements&#8221; within the meaning of section 27A of the Securities Act of 1933 and section<\/em><br \/>\n        <em>21E<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Securities<\/em><br \/>\n        <em>Exchange<\/em><br \/>\n        <em>Act<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>1934.<\/em><br \/>\n        <em>The<\/em><br \/>\n        <em>Company<\/em><br \/>\n        <em>has<\/em><br \/>\n        <em>tried<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>identify<\/em><br \/>\n        <em>such<\/em><br \/>\n        <em>forward-looking<\/em><br \/>\n        <em>statements<\/em><br \/>\n        <em>by<\/em><br \/>\n        <em>use of such words as &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;hopes,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;evidences&#8221; and &#8220;estimates,&#8221; and other similar expressions, but these words are not the exclusive means of identifying such<\/em><br \/>\n        <em>statements.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Important<\/em><br \/>\n        <em>factors<\/em><br \/>\n        <em>that<\/em><br \/>\n        <em>could<\/em><br \/>\n        <em>cause<\/em><br \/>\n        <em>actual<\/em><br \/>\n        <em>results<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>differ<\/em><br \/>\n        <em>materially<\/em><br \/>\n        <em>from<\/em><br \/>\n        <em>those<\/em><br \/>\n        <em>indicated<\/em><br \/>\n        <em>by<\/em><br \/>\n        <em>such<\/em><br \/>\n        <em>forward-looking<\/em><br \/>\n        <em>statements are<\/em><br \/>\n        <em>described<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>sections<\/em><br \/>\n        <em>titled<\/em><br \/>\n        <em>\u201cRisk<\/em><br \/>\n        <em>Factors\u201d<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company\u2019s<\/em><br \/>\n        <em>filings<\/em><br \/>\n        <em>with<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>SEC,<\/em><br \/>\n        <em>including<\/em><br \/>\n        <em>its<\/em><br \/>\n        <em>most<\/em><br \/>\n        <em>recent<\/em><br \/>\n        <em>Annual<\/em><br \/>\n        <em>Report on<\/em><br \/>\n        <em>Form<\/em><br \/>\n        <em>20-F<\/em><br \/>\n        <em>as<\/em><br \/>\n        <em>well<\/em><br \/>\n        <em>as<\/em><br \/>\n        <em>reports<\/em><br \/>\n        <em>on<\/em><br \/>\n        <em>Form<\/em><br \/>\n        <em>6-K,<\/em><br \/>\n        <em>including,<\/em><br \/>\n        <em>but<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>limited<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>following:<\/em><br \/>\n        <em>statements<\/em><br \/>\n        <em>relating<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company&#8217;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&#8217;s<\/em><br \/>\n        <em>drug<\/em><br \/>\n        <em>development<\/em><br \/>\n        <em>program,<\/em><br \/>\n        <em>including,<\/em><br \/>\n        <em>but<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>limited<\/em><br \/>\n        <em>to,<\/em><br \/>\n        <em>ATH434,<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>any<\/em><br \/>\n        <em>other<\/em><br \/>\n        <em>statements<\/em><br \/>\n        <em>that<\/em><br \/>\n        <em>are<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>historical facts.<\/em><br \/>\n        <em>Such<\/em><br \/>\n        <em>statements<\/em><br \/>\n        <em>involve<\/em><br \/>\n        <em>risks<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>uncertainties,<\/em><br \/>\n        <em>including,<\/em><br \/>\n        <em>but<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>limited<\/em><br \/>\n        <em>to,<\/em><br \/>\n        <em>those<\/em><br \/>\n        <em>risks<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>uncertainties<\/em><br \/>\n        <em>relating<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>the difficulties<\/em><br \/>\n        <em>or<\/em><br \/>\n        <em>delays<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em>financing,<\/em><br \/>\n        <em>development,<\/em><br \/>\n        <em>testing,<\/em><br \/>\n        <em>regulatory<\/em><br \/>\n        <em>approval,<\/em><br \/>\n        <em>production<\/em><br \/>\n        <em>and<\/em><br \/>\n        <em>marketing<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company\u2019s<\/em><br \/>\n        <em>drug components,<\/em><br \/>\n        <em>including,<\/em><br \/>\n        <em>but<\/em><br \/>\n        <em>not<\/em><br \/>\n        <em>limited<\/em><br \/>\n        <em>to,<\/em><br \/>\n        <em>ATH434,<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>ability<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>procure<\/em><br \/>\n        <em>additional<\/em><br \/>\n        <em>future<\/em><br \/>\n        <em>sources<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#8217;s drug compounds, including, but not limited<\/em><br \/>\n        <em>to,<\/em><br \/>\n        <em>ATH434,<\/em><br \/>\n        <em>that<\/em><br \/>\n        <em>could<\/em><br \/>\n        <em>slow<\/em><br \/>\n        <em>or prevent products<\/em><br \/>\n        <em>coming<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>market,<\/em><br \/>\n        <em>the uncertainty<\/em><br \/>\n        <em>of obtaining patent protection<\/em><br \/>\n        <em>for<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>Company&#8217;s intellectual<\/em><br \/>\n        <em>property<\/em><br \/>\n        <em>or<\/em><br \/>\n        <em>trade<\/em><br \/>\n        <em>secrets, the uncertainty of successfully enforcing the Company\u2019s patent rights and the uncertainty of the Company freedom to operate.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks<\/em><br \/>\n        <em>only<\/em><br \/>\n        <em>as<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>the<\/em><br \/>\n        <em>date<\/em><br \/>\n        <em>on<\/em><br \/>\n        <em>which<\/em><br \/>\n        <em>it<\/em><br \/>\n        <em>is<\/em><br \/>\n        <em>made.<\/em><br \/>\n        <em>We<\/em><br \/>\n        <em>undertake<\/em><br \/>\n        <em>no<\/em><br \/>\n        <em>obligation<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>publicly<\/em><br \/>\n        <em>update<\/em><br \/>\n        <em>any<\/em><br \/>\n        <em>forward-looking<\/em><br \/>\n        <em>statement, whether<\/em><br \/>\n        <em>written<\/em><br \/>\n        <em>or<\/em><br \/>\n        <em>oral,<\/em><br \/>\n        <em>that<\/em><br \/>\n        <em>may<\/em><br \/>\n        <em>be<\/em><br \/>\n        <em>made<\/em><br \/>\n        <em>from<\/em><br \/>\n        <em>time<\/em><br \/>\n        <em>to<\/em><br \/>\n        <em>time,<\/em><br \/>\n        <em>whether<\/em><br \/>\n        <em>as<\/em><br \/>\n        <em>a<\/em><br \/>\n        <em>result<\/em><br \/>\n        <em>of<\/em><br \/>\n        <em>new<\/em><br \/>\n        <em>information,<\/em><br \/>\n        <em>future<\/em><br \/>\n        <em>developments<\/em><br \/>\n        <em>or otherwise.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjUwNDRkNTctNjY4ZC00YzU5LWEyYjctMDUyNGQ4ZTFkN2E0LTEyNjgyNjItMjAyNi0xMC0zMC1lbg==\/tiny\/ALTERITY-THERAPEUTICS-LIMITED.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted for ATH434, extending protection to 2045 and supporting future development in Parkinson\u2019s disease Peer-reviewed publication in Clinical Autonomic Research from the bioMUSE Natural History Study linked skin \u03b1-synuclein deposition to autonomic dysfunction in early MSA Phase 3 operational activities underway Continued evaluation of strategic funding and partnering alternatives to support Phase\u00a03 development and maximize long-term shareholder value Cash balance of A$41.3 million at 30 September 2026, inclusive of A$3.98 million Australian R&amp;D Tax Incentive refund and approximately net A$5.5 million raised through the exercise of ATHO listed options MELBOURNE, Australia and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015695","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted for ATH434, extending protection to 2045 and supporting future development in Parkinson\u2019s disease Peer-reviewed publication in Clinical Autonomic Research from the bioMUSE Natural History Study linked skin \u03b1-synuclein deposition to autonomic dysfunction in early MSA Phase 3 operational activities underway Continued evaluation of strategic funding and partnering alternatives to support Phase\u00a03 development and maximize long-term shareholder value Cash balance of A$41.3 million at 30 September 2026, inclusive of A$3.98 million Australian R&amp;D Tax Incentive refund and approximately net A$5.5 million raised through the exercise of ATHO listed options MELBOURNE, Australia and &hellip; Continue reading &quot;Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-30T11:56:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update\",\"datePublished\":\"2026-10-30T11:56:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/\"},\"wordCount\":1812,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/\",\"name\":\"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=\",\"datePublished\":\"2026-10-30T11:56:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update - Market Newsdesk","og_description":"Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted for ATH434, extending protection to 2045 and supporting future development in Parkinson\u2019s disease Peer-reviewed publication in Clinical Autonomic Research from the bioMUSE Natural History Study linked skin \u03b1-synuclein deposition to autonomic dysfunction in early MSA Phase 3 operational activities underway Continued evaluation of strategic funding and partnering alternatives to support Phase\u00a03 development and maximize long-term shareholder value Cash balance of A$41.3 million at 30 September 2026, inclusive of A$3.98 million Australian R&amp;D Tax Incentive refund and approximately net A$5.5 million raised through the exercise of ATHO listed options MELBOURNE, Australia and &hellip; Continue reading \"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-30T11:56:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update","datePublished":"2026-10-30T11:56:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/"},"wordCount":1812,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/","name":"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=","datePublished":"2026-10-30T11:56:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NjgwMiM3OTI2MTA3IzIyNTY3MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-releases-appendix-4c-q1-fy27-quarterly-cash-flow-report-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alterity Therapeutics Releases Appendix 4C \u2013 Q1 FY27 Quarterly Cash Flow Report &amp; Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015695"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015695\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}